TransMedics Group, Inc. $TMDX Stock Sold by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC reduced its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 13.3% during the third quarter, Holdings Channel reports. The fund owned 267,282 shares of the company’s stock after selling 41,109 shares during the period. Zevenbergen Capital Investments LLC’s holdings in TransMedics Group were worth $22,305,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in TMDX. Braidwell LP increased its holdings in shares of TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after buying an additional 280,324 shares during the period. Deutsche Bank AG bought a new position in shares of TransMedics Group in the second quarter worth approximately $14,415,000. Bank of New York Mellon Corp bought a new position in shares of TransMedics Group in the second quarter worth approximately $12,869,000. Legal & General Group Plc purchased a new position in shares of TransMedics Group in the second quarter worth $5,286,000. Finally, FirstWave Capital Management LLC increased its stake in shares of TransMedics Group by 53.9% in the second quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock worth $12,702,000 after buying an additional 66,972 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 2.6%

TMDX traded down $2.07 during trading on Thursday, reaching $79.00. The stock had a trading volume of 949,379 shares, compared to its average volume of 1,008,943. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 1.10 and a beta of 1.94. The stock’s 50 day moving average is $85.98 and its two-hundred day moving average is $83.97. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same quarter in the previous year, the business earned $0.92 earnings per share. The firm’s revenue was up 20.7% compared to the same quarter last year. As a group, analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TMDX shares. Canaccord Genuity Group reissued a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. Barclays assumed coverage on TransMedics Group in a report on Wednesday. They set an “overweight” rating and a $120.00 price target on the stock. Stifel Nicolaus increased their price objective on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, TD Cowen restated a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and a consensus price target of $121.00.

Insider Transactions at TransMedics Group

In related news, Director David Weill bought 1,336 shares of the company’s stock in a transaction on Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.